Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Haas, Rainer [VerfasserIn]   i
 Murea, Simona [VerfasserIn]   i
 Goldschmidt, Hartmut [VerfasserIn]   i
 Döhner, Hartmut [VerfasserIn]   i
 Moos, Marion [VerfasserIn]   i
 Witt, Barbara Ingeborg [VerfasserIn]   i
 Hunstein, Werner [VerfasserIn]   i
 Engenhart, Rita [VerfasserIn]   i
 Wannenmacher, Michael [VerfasserIn]   i
Titel:High-dose therapy with peripheral blood progenitor cell support in patients with non-hodgkin's lymphoma
Verf.angabe:Rainer Haas, Simona Murea, Hartmut Goldschmidt, Hartmut Döhner, Marion Moos, Barbara Witt, Werner Hunstein, Rita Engenhart, Michael Wannenmacher
Jahr:1995
Umfang:8 S.
Fussnoten:Gesehen am 04.11.2024
Titel Quelle:Enthalten in: Stem cells
Ort Quelle:Oxford : Oxford University Press, 1993
Jahr Quelle:1995
Band/Heft Quelle:13(1995), suppl. 3, Seite 28-35
ISSN Quelle:1549-4918
Abstract:Between September 1991 and April 1995, high-dose therapy with peripheral blood progenitor cell (PBPC) support was administered to 105 patients with non-Hodgkin's lymphoma (NHL). Thirty-three patients had high-grade NHL, while 72 patients had different forms of low- or intermediate-grade NHL. Except for three patients who received G-CSF during steady-state hematopoiesis, PBPCs were collected following cytokine-supported cytotoxic chemotherapy. This included G-CSF or the sequential administration of interleukin 3 (IL-3) and GM-CSF. Assessing bone marrow (BM) samples before the start of chemotherapy and leukapheresis (LP) products collected during cytokine-enhanced marrow recovery, a 2.3-fold greater mean concentration of CD34+ cells was found in peripheral blood (p < 0.005). The blood-derived progenitor cells were enriched with a particular subset of more primitive progenitors, as the mean proportion of CD34+Thy-1+ cells in LP products was three-fold greater in comparison to premobilization BM samples, respectively (p < 0.001). In contrast, the mean proportion of CD34+/CD19+ and CD19+ cells in LP products was 8.8- and 80-fold smaller compared to BM samples, respectively (p < 0.001). Following high-dose conditioning therapy including TBI in 74 patients, reinfusion of PBPC resulted in rapid and sustained engraftment in the majority of patients, while in seven patients an unsubstituted platelet count of greater than 20 x 109/1 was reached between 31 and 51 days. Five patients died of treatment-related complications between 13 and 188 days following transplantation. The probability of long-term disease-free survival at 30 months in patients autografted while they were in first remission was 70% in high-grade and 83% in low-grade NHL, respectively. The data may provide the rationale for the use of PBPC-supported high-dose regimens as first-line treatment for patients at high risk of treatment failure.
DOI:doi:10.1002/stem.5530130706
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1002/stem.5530130706
 DOI: https://doi.org/10.1002/stem.5530130706
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1907448942
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69269300   QR-Code
zum Seitenanfang